No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis

Gynecologic Oncology

Volumn 68, Issue 1, 1998, Pages 14-17

  Ryan, Andy ^a   Al Jehani, Rajai M ^a   Mulligan, Kellie T ^a   Jacobs, Ian J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DINUCLEOTIDE; DNA; DNA MARKER; MICROSATELLITE DNA;

ARTICLE; CARCINOGENESIS; DNA METHYLATION; FEMALE; GENE REPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031888206     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4881     Document Type: Article

References (29)

1. Miller C W, Aslo A, Campbell M J, Kawamata N, Lampkin B C, Koeffler H P. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Gene Cytogenet. 86:1996;136-142.
2. Dellaragione F, Mercurio C, Iolascon A. Cell-cycle regulation and human leukemias - the role of p16(ink4) gene inactivation in the development of human acute lymphoblastic-leukemia. Haematologica. 80:1995;557-568.
3. Bartek J, Lukas J, Strauss M. A common path to tumor growth - deregulation of rb-dependent restriction point control (review). Oncol Rep. 3:1996;237-240.
4. Fountain J W, Karayiorgou M, Ernstoff M S, Kirkwood J M, Vlock D R, Titus E L, Bouchard B, Vijayasaradhi S, Houghton A N, Lahti J, Kidd V J, Housman D E, Dracopoli N C. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA. 89:1992;10557-10561.
5. Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin S B, Sidransky D. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res. 54:1994;2322-2326.
6. Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res. 55:1995;224-227.
7. Dreyling M H, Bohlander S K, Le Beau M, Olopade O I. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood. 86:1995;1931-1938.
8. Gonzalez M V, Pello M F, Lopezlarrea C, Suarez C, Menendez M J, Coto E. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous-cell carcinoma of the head and neck. Clin Cancer Res. 1:1995;1043-1049.
9. Rosin M P, Cairns P, Epstein J I, Schoenberg M P, Sidransky D. Partial allelotype of carcinomain-situ. Cancer Res. 55:1995;5213-5216.
10. Devlin J, Elder P A, Gabra H, Steel C M, Knowles M A. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumor-suppressor loci. Br J Cancer. 73:1996;420-423.
11. Devos S, Miller C W, Takeuchi S, Gombart A F, Cho S K, Koeffler H P. Alterations of cdkn2 (p16) in non-small-cell lung-cancer. Genes Chromosomes Cancer. 14:1995;164-170.
12. Takeuchi S, Bartram C R, Seriu T, Miller C W, Tobler A, Janssen J, Reiter A, Ludwig W D, Zimmermann M, Schwaller J, Lee E, Miyoshi I, Koeffler H P. Analysis of a family of cyclin-dependent kinase inhibitors -p15/mts2/ink4b, p16/mts1/ink4a, and p18 genes in acute lymphoblastic- leukemia of childhood. Blood. 86:1995;755-760.
13. Loughran O, Malliri A, Owens D, Gallimore P H, Stanley M A, Ozanne B, Frame M C, Parkinson E K. Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene. 13:1996;561-568.
14. Okajima E, Fukuda T, Okita S, Tsutsumi M, Hirao Y, Okajima E, Konishi Y. Infrequent somatic alteration of p16/mts1 in human primary superficial bladder cancers. Cancer Lett. 103:1996;227-231.
15. Pollock P M, Pearson J V, Hayward N K. Compilation of somatic mutations of the cdkn2 gene in human cancers - nonrandom distribution of base substitutions. Genes Chromosomes Cancer. 15:1996;77-88.
16. Campbell I G, Beynon G, Davis M, Englefield P. LOH and mutation analysis of cdkn2 in primary human ovarian cancers. Int J Cancer. 63:1995;222-225.
17. Rodabaugh K J, Biggs R B, Qureshi J A, Barrett A J, Welch W R, Bell D A, Berkowitz R S, Mok S C. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene. 11:1995;1249-1254.
18. Schultz D C, Vanderveer L, Buetow K H, Boente M P, Ozols R F, Hamilton T C, Godwin A K. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res. 55:1995;2150-2157.
19. Ichikawa Y, Yoshida S, Koyama Y, Hirai M, Ishikawa T, Nishida M, Tsunoda H, Kubo T, Miwa M, Uchida K. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer. 69:1996;466-470.
20. ink4) gene alterations in human ovarian tumors. Br J Cancer. 74:1996;1069-1073.
21. Merlo A, Herman J G, Mao L, Lee D J, Gabrielson E, Burger P C, Baylin S B, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1:1995;686-692.
22. Costello J F, Berger M S, Huang H, Cavenee W K. Silencing of p16/cdkn2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56:1996;2405-2410.
23. Lo K W, Cheung S T, Leung S F, Vanhasselt A, Tsang Y S, Mak K F, Chung Y F, Woo J, Lee J, Huang D P. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 56:1996;2721-2725.
24. Herman J G, Merlo A, Mao L, Lapidus R G, Issa J P, Davidson N E, Sidransky D, Baylin S B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530.
25. Weitzel J N, Patel J, Smith D M, Goodman A, Safaii H, Ball H G. Molecular-genetic changes associated with ovarian cancer. Gynecol Oncol. 55:1994;245-252.
26. Osborne R J, Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer. 69:1994;429-438.
27. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 380:1996;152-154.
28. Gnarra J R, Tory K, Weng Y, Schmidt L, Wei M H, Li H, Latif F, Liu S, Chen F, Duh F M, Lubensky I, Duan D R, Florence C, Pozzatti R, Walther M M, Bander N H, Grossman H B, Brauch H, Pomer S, Brooks J D, Isaacs W B, Lerman M I, Zbar B, Linehan W M. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nature Genet. 7:1994;85-90.
29. Herman J G, Latif F, Weng Y, Lerman M I, Zbar B, Lui S, Samid D, Duan D R, Gnarra J R, Linehan W M, Baylin S B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 91:1994;9700-9704.